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Cotinine inhibits the pro-inflammatory response
initiated by multiple cell surface Toll-like
receptors in monocytic THP cells
Juhi Bagaitkar1,3, Iris Zeller2, Diane E Renaud2 and David A Scott1,2*

Abstract
Background: The primary, stable metabolite of nicotine [(S)-3-(1-methyl-2-pyrrolidinyl) pyridine] in humans is
cotinine [(S)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone]. We have previously shown that cotinine exposure induces
convergence and amplification of the GSK3β-dependent PI3 kinase and cholinergic anti-inflammatory systems. The
consequence is reduced pro-inflammatory cytokine secretion by human monocytes responding to bacteria or LPS,
a TLR4 agonist.
Findings: Here we show that cotinine-induced inflammatory suppression may not be restricted to individual
Toll-like receptors (TLRs). Indeed, in monocytic cells, cotinine suppresses the cytokine production that is normally
resultant upon agonist-specific engagement of all of the major surface exposed TLRs (TLR 2/1; 2/6; 4 and 5),
although the degree of suppression varies by TLR.
Conclusions: These results provide further mechanistic insight into the increased susceptibility to multiple bacterial
infections known to occur in smokers. They also establish THP-1 cells as a potentially suitable model with which to
study the influence of tobacco components and metabolites on TLR-initiated inflammatory events.
Keywords: Cholinergic anti-inflammatory pathway, Cotinine, Cytokines, GSK3β, Inflammation, THP-1 cells,
Tobacco smoking, Toll-like receptors

Findings
Introduction

The ability to regulate against prolonged or excessive inflammation is critical in preventing the onset of septic
shock and the host-mediated damage associated with
multiple chronic inflammatory diseases. On the other
hand, a reduced inflammatory capacity can lead to an
inability to clear pathogens and can compromise tissue
remodeling [1].
In recent years the importance of the cholinergic antiinflammatory system in modulating cytokine production
in response to inflammatory stimuli has become apparent.
The cholinergic anti-inflammatory pathway suppresses
inflammation through the activation of the α7 nicotinic
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acetylcholine receptor (α7nAChR) on innate immune cells
by neuronal and / or locally produced acetylcholine [1-4].
Nicotine, a major component of cigarette smoke, is also
a potent α7nAChR agonist [5,6]. Smokers are more susceptible to multiple bacterial diseases than non-smokers
[7]. The inappropriate activation of the cholinergic antiinflammatory pathway by nicotine provides mechanistic
insight into this phenomenon. Nicotine is rapidly converted into multiple metabolites in humans. Of these, cotinine, a considerably more stable molecule than nicotine
that frequently reaches concentrations in the blood of
> 500 ng/ml in tobacco smokers, is the most common [8].
We have previously shown that cotinine dramatically
alters the nature of the inflammatory response to Gram
negative bacteria in human innate cells [6]. Cotinine abrogates the production of cytokines that are under the
transcriptional control of the NFκB system (TNF-α,
IL-1β, IL-6, IL-12/IL-23 p40) and shifts the response towards an IL-10-dominated, anti-inflammatory profile in
primary human monocytes stimulated with Porphyromonas
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Figure 1 Cotinine-induced suppression of cytokine induction on specific stimulation of TLRs. TNF secretion was monitored following
stimulation with TLR specific agonists at 1μg/ml (A, Pam2CGDPKHPKSF [TLR2/1]; B, FSL [TLR2/6); C, LPS [TLR4]; and D, flagellin [TLR5]) with and
without cotinine pre-incubation (10–1000 ng/ml, 2 hr). Results are presented as percentage of TLR2/1, TLR2/6, TLR4 and TLR 5 agonist alone.
100% represents (mean ± s.d.) 25568 ± 1560 ng/ml, 10347 ± 2842 ng/ml, 4671 ± 117 ng/ml and 1583 ± 176 ng/ml for Pam2CGDPKHPKSF, FSL,
LPS and flagellin, respectively. */**/*** p < 0.05, 0.01 and 0.001, respectively, compared to agonist only.

gingivalis or LPS. This anti-inflammatory phenomenon is
initiated upon engagement of leukocytic α7 nAChRs and is
PI3K/GSK-3β-dependent but NFκB-independent [6].
Innate cells express multiple TLRs that recognize variant microbial-associated molecular patterns and induce
the inflammatory response to pathogens, which is reflected in an increased secretion of pro-inflammatory cytokines. While cotinine represses the cytokine response to
intact Gram negative bacteria, the specific TLRs whose
cytokine output is manipulated by cotinine have yet to be
established. Since its introduction in 1980 [9], the human

monocytic-derived THP-1 cell line has been routinely
used to study the functions of mononuclear innate cells
in vitro. THP-1 cells are capable of further differentiation into macrophage-, foam cell- and osteoclast-like cells
[10,11]. THP-1 cells express all surface-exposed TLR subunits (1, 2, 4, 5 and 6) [12,13] but do not have the genetic
variation in TLRs noted in primary innate cells [14]. Furthermore, THP-1 cells are responsive to inflammatory
stimuli [10,13]. Thus, THP-1 cells may represent a suitable
model with which to study the effects of tobacco alkaloids
and other anti-inflammatory agents that act via nicotinic
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receptors to subvert TLR signaling events. As the specific
TLRs whose cytokine output is manipulated by cotinine
have yet to be established and because we wished to see
if THP-1 may be a useful model with which to study
tobacco alkaloid-mediated immune suppression, the
influence of cotinine on cytokine secretion upon stimulation of multiple TLRs was determined in THP-1
cells. Initially, we have focused on the surface exposed
TLRs, rather than nucleotide oligomerization domainlike receptors (NLRs), retinoic acid-inducible protein
1-like receptors (RLRs) and cytosolic TLRs.

Methods
Growth and maintenance of THP-1 cells

THP-1 cells (Invivogen, San Diego, CA) were cultured in
RPMI 1640 medium supplemented with 10% heat inactivated FBS, 50 μM 2-mercaptoethanol, 1 mM sodium
pyruvate, 2 mM L-glutamine, 20 mM HEPES, 50 U/ml
of penicillin and 50 μg/ml of streptomycin and maintained at 37°C, 5% CO2.
Influence of cotinine on TLR-specific cytokine output

0.5 x 106 THP-1 cells per well were seeded in 96-well
plates and stimulated with human TLR-specific agonists (Pam3CSK4 [TLR2/1]; FSL-1 [Pam2CGDPKHPKSF,
TLR2/6); Escherichia coli K12 LPS [TLR4]; and Salmonella
typhimurium flagellin [TLR5]; all Invivogen) at 1 μg/ml
with or without a 2 hour pre-incubation with cotinine
(10–1000 ng/ml; Sigma-Aldrich, St. Louis, MO). TNF
levels were determined in 24 hr supernatants by ELISA
(eBioscience, San Diego, CA).
Statistical approaches

Statistical significance between groups was evaluated by
ANOVA using the InStat program (GraphPad Software,
San Diego, CA). Differences between groups were considered significant at the level of p < 0.05.

Results and discussion
The ability of cotinine to suppress TNF secretion on engagement of TLR2/1, -2/6, -4 and −5 by TLR-specific cognizant ligands was determined. Concentrations of TNF
secreted into 24 hour cell-free supernatants in unstimulated cells (mean, s.d. 495, 79 pg/ml) and those stimulated
with 10, 100 and 1000 ng/ml cotinine alone (mean, s.d.
729, 157; 744, 122; and 838, 121 pg/ml, respectively) were
minimal. Therefore, cotinine itself does not induce meaningful TNF release from monocytic cells.
Cotinine suppressed TNF release in response to TLR2/1,
TLR2/6, TLR4 and TLR5 agonists - Pam2CGDPKHPKSF
(a synthetic diacylated lipoprotein); FSL (a synthetic triacylated lipoprotein), E. coli LPS and S. typhimurium flagellin, respectively – in a dose-related manner, as
shown in Figure 1A-D. These results are consistent with
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the prior finding that cotinine suppresses pro-inflammatory
cytokines and promotes IL-10 production in TLR4stimulated primary human monocytes [6]. However, it
should be noted that the degree of suppression varied by
TLR and cytokine inhibition was less impressive than in
primary cells. Also of interest is the observation by Noakes
et al. that the ability of cord blood mononuclear cells to respond to TLR agonists is inversely proportional to the
maternal smoking load [15]. Indeed, the cotinine doses
employed herein are physiologically relevant to smokers
(up to 1000 ng/ml, systemically) and those exposed to
second-hand smoke (</= 10 ng/ml, systemically) [8].
Thus, this study furthers our understanding of how
tobacco smoke exposure renders individuals more susceptible to bacterial infection by, e.g., Streptococcus pneumonia, Neisseria meningitidis, Haemophilus influenza,
Legionella pneumophila, Helicobacter pylori and Mycobacterium tuberculosis [7].
It will be important, in the future, to perform similar
studies in leukocytes from smoking and non-smoking
humans. However, and more importantly, these findings
are relevant to the expansive ongoing research aimed at
exploitation of endogenous anti-inflammatory pathway(s)
to either up-regulate or down-regulate the production of
specific cytokine groups (pro- or anti-inflammatory cytokines) depending on the clinical necessity. Indeed, such
therapeutic advances may be useful to both smokers and
non-smokers, alike. To this end, THP-1 cells may represent
a useful model with which to study anti-inflammatory
agents that act via modulation of innate cell nicotinic receptor signaling pathways.
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